OncoMatch/Clinical Trials/NCT06415318
TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Is NCT06415318 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Paclitaxel + Ifosfamide + Cisplatin & Toripalimab for penile cancer.
Treatment: Paclitaxel + Ifosfamide + Cisplatin & Toripalimab — Primary Objective: To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with Toripalimab as a neoadjuvant treatment in locally advanced penile cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Penile Carcinoma
Disease stage
Required: Stage T4, ANY N, ANY T, N3
Clinical Stage is Locally advanced penile cancer (T4, any N stage; or any T stage, N3)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: time from last chemotherapy to relapse > 12 months
No prior chemotherapy for newly diagnosed or relapsed patients or the time from the last chemotherapy to relapse should be longer than 12 months
Cannot have received: experimental drug
Previously received any other experimental drug treatment within 4 weeks before enrollment
Lab requirements
Blood counts
hemoglobin(hb) >= 80g/l; white blood cell count >= 3.0x10^9/l; neutrophil count >= 1.5x10^9/l; platelet count >= 100x10^9/l
Liver function
ast, alt, alp <= 2.5 uln; total bilirubin <= 1.5 uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify